drugset / Trial / NCT05128409
Phase I of XKH001Injection in Healthy Adults
RandomizedSequentialTriple-blindHealth-services research
Summary
XKH001is a recombinant humanized monoclonal IgG1 antibody for subcutaneous injection. XKH001 specifically blocks interleukin-25 from binding to its receptors. To evaluate the safety, tolerability, pharmacokinetics (PK) of single ascending doses of XKH001 injection following subcutaneous administration
Timeline
- Start
- 2023-03-07
- Primary completion
- 2024-10-01
- Completion
- 2024-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | XKH001 | Monoclonal antibody | 0.5 mg/kg | Subcutaneous |
| Comparator | XKH001 | Monoclonal antibody | 1.67 mg/kg | Subcutaneous |
| Comparator | XKH001 | Monoclonal antibody | 3.34 mg/kg | Subcutaneous |
| Comparator | XKH001 | Monoclonal antibody | 5 mg/kg | Subcutaneous |
| Comparator | XKH001 | Monoclonal antibody | 10 mg/kg | Subcutaneous |
Indications
No indication recorded.